GOVX

Business Context and Reporting Period

Company: Dauphin Technology, Inc. (Note: Metadata referenced Geovax Labs, Inc., but the filing is for Dauphin Technology, Inc., which entered a merger agreement with GeoVax in January 2006).

Reporting Period: Fiscal year ended December 31, 2005.

Status: The Company is classified as a development-stage entity with no active operations since December 2003. Previous operations involved mobile hand-held computers and set-top boxes, which were terminated due to financial failure. The Company is currently seeking a merger or acquisition, specifically a pending merger with GeoVax, Inc., a biotechnology firm.

Key Financial Metrics (Year Ended Dec 31, 2005)

Material Changes vs. Prior Period (2004)

• Revenue: Remained at $0 for both 2005 and 2004 as operations were discontinued in late 2003.
• Net Loss: Total net loss decreased from $(2,207,806) in 2004 to $(1,408,534) in 2005. The 2004 loss included $(548,865) from discontinued operations, whereas 2005 had no discontinued operations.
• Expenses: General and administrative expenses decreased significantly from approximately $1,549,000 in 2004 to $876,000 in 2005, largely due to reduced payments to consultants and former employees.
• Interest Expense: Decreased from $337,000 in 2004 to $62,000 in 2005, primarily due to the completion of debt discount amortization in 2004.
• Derivative Liability: Increased from $760,565 in 2004 to $1,231,158 in 2005, contributing to a loss of $470,593 in 2005 compared to a gain of $227,197 in 2004.
• Capital Structure: Issued 10,000,000 shares of Series A Preferred Stock in 2005 for $550,000. Issued $626,400 in new convertible loans.

Outlook, Risks, and Management Commentary

• Going Concern: The Company's auditors have expressed substantial doubt about its ability to continue as a going concern due to recurring losses, negative cash flows, and a significant working capital deficit.
• Merger with GeoVax: In January 2006, Dauphin entered a definitive merger agreement with GeoVax, Inc. (HIV vaccine developer). Completion is contingent on shareholder approval. There is no assurance the merger will close or that the surviving entity will be successful.
• Liquidity: The Company has no revenue and relies entirely on debt and equity financing to fund operations. It anticipates continuing to issue debt and stock to sustain operations.
• Capital Deficiency: The Company lacks sufficient authorized common stock to satisfy obligations from outstanding warrants and convertible debt without a shareholder vote to amend its Articles of Incorporation.
• Legal Proceedings: In March 2006, the Company filed suit against preferred shareholders and investment bankers alleging fraud and breach of fiduciary duty regarding the GeoVax merger. This was settled in May 2006, confirming the merger path and cancelling a $1.3 million convertible note.
• Internal Controls: The new auditor (Porter Keadle Moore, LLP) identified material weaknesses in internal controls, including segregation of duties and accounting record maintenance.

Investor Verification Checklist

• Verify the status of the merger agreement with GeoVax, Inc., including shareholder approval outcomes.
• Confirm the Company's ability to raise additional capital given the lack of authorized common stock for conversions.
• Assess the validity and enforceability of the $3.0 million in convertible loans and $1.2 million derivative liability.
• Review the settlement terms of the May 2006 litigation regarding the cancellation of the $1.3 million note.
• Monitor the Company's cash burn rate against its current cash balance of $78,381.